
L'aumento del prezzo di Mounjaro lascia i pazienti nel Regno Unito con bollette elevate
Revisione paritaria di Dr Colin Tidy, MRCGPAutore Thomas Andrew Porteus, MBCSPubblicato originariamente 14 Ago 2025
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Aggiungi alle fonti preferite su Google
If you buy the weight-loss medicine Mounjaro privately in the UK you may see a steep price increase from September. The change will not affect you if you get your medicine from the NHS.
Here we show what are the alternatives and what you need to think about if you change or stop taking medicines.
What is Mounjaro and who uses it?
Mounjaro is the brand name for tirzepatide, a medicine that mimics hormones in your body to help control blood sugar and reduce appetite. It’s given by weekly injection and is licensed for type 2 diabetes and for weight loss and weight management in adults aged 18 and over.
Mounjaro is authorised for adult patients with a BMI of 30 or more (obesity), as well as those with a BMI between 27-30 (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.
At the moment, more than 1.5 million people in the UK use weight-loss medicines. Mounjaro is the most popular. Around 9 out of 10 people getting it do so privately, often through online providers or high-street pharmacies.
Cosa sta cambiando?
From September, the manufacturer Eli Lilly is putting up the price. The highest dose, which is one of the most commonly used, will increase from around £122 to £330 per month - a rise of around 170%. Lower doses will also cost more, but the increases will be smaller.
These changes only apply to people buying the drug privately and not those getting the medicine on the NHS. NHS prices are agreed in separate deals and will stay the same.
Why is this happening?
Eli Lilly says the current private price in the UK was always temporary. The company initially set it low to help people access the drug earlier. Now that more research is available, and the drug has been launched in more countries, they say the UK price needs to match what other countries pay.
The manufacturer also said the price change was partly influenced by the global debate around medicine costs. In the US, President Donald Trump has suggested linking medicine prices to what’s paid in other countries. Eli Lilly says it supports fair pricing, but does not think that approach works in practice.
What are the alternatives?
Wegovy is a different injectable weight-loss medicine, made by Novo Nordisk. It works in a similar way and is also available on private prescription in the UK. Some people may find it easier to access or afford than Mounjaro, depending on the dose and provider.
Other options include tablets such as orlistat, as well as lifestyle support services offered by the NHS or local councils. Not all treatments work in the same way, and they’re not right for everyone, so it’s important to get proper advice.
What should you do next?
If you’re using Mounjaro and worried about the cost, speak to your doctor or pharmacist. They can help you review your treatment and talk through other options.
Do not stop your injections suddenly without getting medical advice. A sudden stop can cause your blood sugar or appetite to change quickly, which might affect your health.
You can also ask about getting treatment through the NHS. Weight-loss medicines are only offered on the NHS in certain situations, but your doctor can explain whether you might qualify.
NHS England has announced that some people will now be able to get the Mounjaro jab from their doctor or at a local clinic.
This applies to people who have:
A BMI of 40 or above - or 37.5 if you are from a minority ethnic group.
Four out of five of the following health conditions - type 2 diabetes, high blood pressure, heart disease, high cholesterol, and sleep apnoea.
Scelte dei pazienti

Notizie sulla salute
Farmaco per il cancro ovarico approvato per l'uso nel NHS prolungherà la vita
A drug that can treat chemotherapy-resistant ovarian cancer has just been approved for use on the NHS in England. Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
di Professor Steve Conlan

Notizie sulla salute
Perché i medici stanno scioperando e come ottenere aiuto se ne hai bisogno
When doctors take part in strike action, it can feel disruptive and, at times, confusing. Headlines often focus on cancellations and delays, but understanding why this is happening can make it easier to navigate. At Patient we think it’s important to give a clearer, more balanced view - both of the reasons behind the strikes and what they mean in practice.
di Thomas Andrew Porteus, MBCS
Informazioni sull'autoreVisualizza il profilo completo

Thomas Andrew Porteus, MBCS
SaluteTech
MBCS
Thomas scrive per informare, ispirare e attrezzare i leader delle pratiche e i professionisti della salute che affrontano il cambiamento, attingendo a due decenni di lavoro pratico nel sistema sanitario del Regno Unito.
Informazioni sul recensoreVisualizza il profilo completo

Dr Colin Tidy, MRCGP
Medico di base, Autore medico
MBBS, MRCGP, MRCP (Paediatrics), DCH
Il Dr Colin Tidy è un medico del NHS, con sede nell'Oxfordshire.
Storia dell'articolo
Le informazioni su questa pagina sono revisionate da clinici qualificati.
Articolo disponibile anche in Inglese, Tedesco, Spagnolo, Francese, Italiano, Portoghese, Hindi, Ebraico, Arabo, and Svedese.
Next review due: 14 Aug 2025
14 Ago 2025 | Pubblicato originariamente
Autore:
Thomas Andrew Porteus, MBCSRevisione paritaria di
Dr Colin Tidy, MRCGP

Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.

Non ti senti bene?
Valuta i tuoi sintomi online gratuitamente
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.
Altre notizie sulla salute
- 1 bambino su 5 che inizia la scuola primaria non è completamente protetto contro malattie gravi
- NuovoMuovere il mignolo può davvero fermare il declino cognitivo?
- Cambiamenti nella cura del diabete di tipo 2 - cosa significa per te
- Hai davvero bisogno di fare 10.000 passi al giorno?
- La stagione influenzale inizia presto: l'UKHSA esorta i gruppi idonei a vaccinarsi
- Per la prima volta, il vaccino gratuito contro la varicella sarà offerto ai bambini in Inghilterra
- NuovoHow to keep your medicines safe during hot weather
- Il morbillo è tornato: perché i vaccini sono importanti
- Prescrizioni di cannabis medica - i fatti dietro i titoli
- MHRA approva teplizumab per ritardare la progressione del diabete di tipo 1
- Aumento del prezzo di Mounjaro: le tue domande risposte
- NuovoFarmaco per il cancro ovarico approvato per l'uso nel NHS prolungherà la vita
- Spiegato il piano sanitario decennale del NHS
- La Carta del Paziente: I tuoi diritti, le promesse e le responsabilità del NHS
- Spiegato il trend ‘nonnamaxxing’ di TikTok: ecco come vivere come una nonna italiana può giovare alla salute e al benessere
- Cosa significa per te il nuovo farmaco generico per il diabete e il cuore: spiegazione del dapagliflozin
- Perché i medici stanno scioperando e come ottenere aiuto se ne hai bisogno